UCB SA (OTCMKTS:UCBJY – Get Free Report) saw a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 7,614 shares, a decrease of 63.8% from the October 15th total of 21,017 shares. Based on an average daily volume of 76,592 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold.
UCB Price Performance
OTCMKTS UCBJY traded up $1.34 during trading on Friday, hitting $163.75. 14,056 shares of the company traded hands, compared to its average volume of 31,350. UCB has a 12 month low of $110.55 and a 12 month high of $168.76. The business has a fifty day simple moving average of $131.08 and a 200 day simple moving average of $140.66.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Jefferies Financial Group upgraded UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, UCB has an average rating of “Buy”.
Check Out Our Latest Stock Report on UCB
UCB Company Profile
UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.
See Also
- Five stocks we like better than UCB
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
